Therapeutic Goods Administration (Australian Government Department of Health), 2025-09-25: Australian regulator safety advisory on unregistered oral methylene blue products imported for cognitive enhancement, mood and anti-ageing, warning of serotonin syndrome, pregnancy risk and G6PD haemolysis, and noting border seizure powers.
These products are being promoted for unapproved (off-label) uses, such as cognitive enhancement, mood improvement, and anti-ageing effects.
web page
Therapeutic Goods Administration (Australian Government Department of Health), 2025-09-25: Australian regulator safety advisory on unregistered oral methylene blue products imported for cognitive enhancement, mood and anti-ageing, warning of serotonin syndrome, pregnancy risk and G6PD haemolysis, and noting border seizure powers. Regulatory safety advisory; the page prints 'Published 25 September 2025'. Read 2026-11-21. Same document as MTH-056, under a different tga.gov.au path. Names the promotional uses (cognitive enhancement, mood, anti-ageing) without naming individual sellers. States methylene blue is prescription-only when presented for injection, that oral imports are unregistered, and that the TGA works with the Australian Border Force to seize non-compliant imports. No specific brand is named on the page. Study type: regulatory record.
